Eugene Braunwald
Affiliations: | 1968 | National Institutes of Health, Bethesda, MD | |
| 1968-1972 | University of California, San Diego School of Medicine, San Diego, CA, United States | ||
| 1972- | Harvard Medical School, Boston, MA, United States |
Website:
http://www.nasonline.org/member-directory/members/57428.htmlGoogle:
"Eugene Braunwald"Bio:
Parents
Sign in to add mentor| Ludwig W. Eichna | research assistant | NYU, Bellevue Hospital | |
| André Frédéric Cournand | research scientist |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jering KS, Claggett BL, Pfeffer MA, et al. (2023) Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circulation. Heart Failure. e010259 |
| Sabatine MS, Braunwald E. (2021) Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. Journal of the American College of Cardiology. 77: 2822-2845 |
| Jering KS, Claggett B, Pfeffer MA, et al. (2021) Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. European Journal of Heart Failure |
| Berardi C, Braunwald E, Morrow DA, et al. (2020) Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. Jacc. Heart Failure |
| Antman EM, Braunwald E. (2020) Invasive or Conservative Strategy for Stable Coronary Disease. Reply. The New England Journal of Medicine. 383: e66 |
| Ambrosy AP, Braunwald E, Morrow DA, et al. (2020) Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Journal of the American College of Cardiology. 76: 1034-1048 |
| Berg DD, Braunwald E, DeVore AD, et al. (2020) Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. Jacc. Heart Failure |
| Gaziano TA, Fonarow GC, Velazquez EJ, et al. (2020) Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. Jama Cardiology |
| Marston NA, Bonaca MP, Jarolim P, et al. (2020) Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. Jama Cardiology |
| Mann DL, Greene SJ, Givertz MM, et al. (2020) Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. Jacc. Heart Failure |